Topas Therapeutics has appointed Rupert Sandbrink as its new chief development officer and chief medical officer, a role that will see him lead the German group’s development and regulatory affairs.
Forging a 20-year-career spanning clinical development, regulatory and medical affairs and pharmacovigilance business, Dr Sandbrink’s expertise saw him most recently at Forward Pharma, where he served as executive vice president, multiple sclerosis/neurology and immunology.
Prior to that, he held several roles at Bayer, including vice president, head of experimental medicine of women’s health and common mechanism research.
Timm Jessen, chief executive officer, Topas, said: “Rupert has a long and successful track record of bringing drugs and biologics through clinical development and regulatory approval.
“He brings the critical expertise and experience that will help us immensely as we advance and prepare to enter our first program into the clinic. I am very excited to have him join the Topas team.”
At Topas, Dr. Sandbrink will guide projects into the clinic, design and execute clinical development programs and trials and lead the interactions with regulatory authorities.